However, increasing evidence suggests that ccRCC response to immunotherapy was independent of the extent of CD8+ T cell infiltration and PD-L1 expression (11) and could not be predicted by tumor mutational burden (TMB), as done in some other cancers (12, 13). The gene discussed is CD8A; the disease is cancer.